CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

Home・Stock List・Ocugen Inc

Ocugen Inc

Closed

1.47 -2.65

Buy Sell

Overview

Share price change

24h

Current

Min

1.45

Max

1.5899999999999999

Key metrics
By Trading Economics
Income	2.3M -18M
Sales	-1.9M -193K
Profit margin	9,174.093
Employees	116
EBITDA	1.5M -16M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+666.23% upside

Dividends
By Dow Jones
Next Earnings	31 Jul 2026

Market Stats
By TradingEconomics
Market Cap	-8.7M 626M
Previous open	4.12
Previous close	1.47

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

0.6818 / 0.74 Support & Resistance

Ocugen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 May 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 May 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 May 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 May 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 May 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 May 2026, 22:32 UTC

Earnings

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 May 2026, 22:02 UTC

Market Talk

Major News Events

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 May 2026, 21:49 UTC

Earnings

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 May 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 May 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 May 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 May 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 May 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 May 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 May 2026, 21:23 UTC

Acquisitions, Mergers, Takeovers

CSG Systems Sale to NEC Gets CFIUS Clearance

11 May 2026, 21:12 UTC

Earnings

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 May 2026, 21:12 UTC

Earnings

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 May 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 May 2026, 20:44 UTC

Earnings

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 May 2026, 20:43 UTC

Earnings

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 May 2026, 20:32 UTC

Earnings

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 May 2026, 20:32 UTC

Earnings

CleanSpark 2Q Rev $136.4M >CLSK

11 May 2026, 20:30 UTC

Earnings

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 May 2026, 20:30 UTC

Earnings

Steris 4Q Cont Ops EPS $2.24 >STE

11 May 2026, 20:30 UTC

Earnings

Steris 4Q Rev $1.6B >STE

11 May 2026, 20:30 UTC

Earnings

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 May 2026, 20:30 UTC

Earnings

Steris 4Q Adj EPS $2.83 >STE

11 May 2026, 20:22 UTC

Hot Stocks

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 May 2026, 19:37 UTC

Earnings

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 May 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer Comparison

Price change

Ocugen Inc Forecast

Price Target

By TipRanks

666.23% upside

12 Months Forecast

Average 11.57 USD 666.23%

High 22 USD

Low 7 USD

Based on 7 Wall Street analysts offering 12 month price targets forOcugen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Ocugen Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.6818 / 0.74Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.